Yoshifumi Seki

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study

Yutaka Osuga, Yoshifumi Seki, Masataka Tanimoto et al. · Fertility and Sterility · 2020 · 91 citations

Medicine, Gynecology, Pharmacotherapy +17

Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

Yutaka Osuga, Yoshifumi Seki, Masataka Tanimoto et al. · BMC Women s Health · 2021 · 32 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +13

Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial

Hiroshi Hoshiai, Yoshifumi Seki, Takeru Kusumoto et al. · BMC Women s Health · 2021 · 29 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study

Nobuya Inagaki, Hiroki Sano, Yoshifumi Seki et al. · Journal of Diabetes Investigation · 2016 · 18 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of once‐weekly oral trelagliptin switched from once‐daily dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: An open‐label, phase 3 exploratory study

Nobuya Inagaki, Hiroki Sano, Yoshifumi Seki et al. · Journal of Diabetes Investigation · 2017 · 15 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17